2RZ Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Poseida Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.59 |
| 52 Week High | US$3.82 |
| 52 Week Low | US$1.46 |
| Beta | 0.46 |
| 1 Month Change | -0.31% |
| 3 Month Change | -32.20% |
| 1 Year Change | 24.52% |
| 3 Year Change | -61.91% |
| 5 Year Change | n/a |
| Change since IPO | -77.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2RZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.3% | 0.7% | -0.8% |
| 1Y | 24.5% | -23.7% | 3.2% |
Return vs Industry: 2RZ exceeded the German Biotechs industry which returned -23.9% over the past year.
Return vs Market: 2RZ exceeded the German Market which returned 3.2% over the past year.
Price Volatility
| 2RZ volatility | |
|---|---|
| 2RZ Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 2RZ's share price has been volatile over the past 3 months.
Volatility Over Time: 2RZ's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 335 | Kristin Yarema | poseida.com |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company’s development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC.
Poseida Therapeutics, Inc. Fundamentals Summary
| 2RZ fundamental statistics | |
|---|---|
| Market cap | €267.23m |
| Earnings (TTM) | -€100.34m |
| Revenue (TTM) | €76.05m |
3.5x
P/S Ratio-2.7x
P/E RatioIs 2RZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2RZ income statement (TTM) | |
|---|---|
| Revenue | US$82.50m |
| Cost of Revenue | US$161.64m |
| Gross Profit | -US$79.14m |
| Other Expenses | US$29.72m |
| Earnings | -US$108.86m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | -95.92% |
| Net Profit Margin | -131.94% |
| Debt/Equity Ratio | 69.4% |
How did 2RZ perform over the long term?
See historical performance and comparison